Abstract
A variety of pragmatic issues can come up when developing budget-impact analyses. Some of these issues can have a substantial impact on drug budgets and can reverse the expected results. Therefore, payers and budget holders may require the consideration of some of these issues in the main analyses. In this chapter, we review three common pragmatic issues: (1) off-label drug use, (2) the impact of adherence and/or persistence, and (3) the importance of understanding the cost perspective. All of these issues should be carefully considered when developing budget-impact analyses for new drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
In this chapter we make the simplifying assumption that the budget-impact analysis is based on the introduction of a new drug to the current mix of drugs for treatment of a condition. Changes in our recommended approaches to estimate the budget impacts of other types of healthcare interventions (i.e., vaccines, diagnostics, surgery, and devices) are discussed in Chap. 13.
References
Celebrex (celecoxib) capsule prescribing information. GD Searle LLC Division of Pfizer Inc.; 2013.
Coumadin (warfarin sodium) prescribing information. Princeton: Bristol-Myers Squibb Company; 2011.
Goettsch WG, Enzing J. Review: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):1–2. doi:10.1016/j.jval.2013.09.003.
Lexapro (escitalopram oxalate) prescribing information. St Louis: Forest Pharmaceuticals Inc., Subsidiary of Forest Laboratories, Inc.; 2014.
Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019–32. doi:10.1111/j.1468-1331.2010.03066.x.
Seroquel (quetiapine fumarate) prescribing information. Wilmington: AstraZeneca; 2013.
Singulair (montelukast sodium) prescribing information. Whitehouse Station: Merck & Co., Inc.; 1998–2012.
Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291.
Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–41.
Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28(12):1443–52. doi:10.1592/phco.28.12.1443.
Watkins JB, Danielson D. Improving the usefulness of budget impact analyses: a U.S. payer perspective. Value Health. 2014;17(1):3–4. doi:10.1016/j.jval.2013.09.007.
Wingerchuk DM. Neuromyelitis optica. Int MS J. 2006;13(2):42–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Earnshaw, S., Mauskopf, J. (2017). Additional Pragmatic Topics. In: Budget-Impact Analysis of Health Care Interventions. Adis, Cham. https://doi.org/10.1007/978-3-319-50482-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-50482-7_12
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-50480-3
Online ISBN: 978-3-319-50482-7
eBook Packages: MedicineMedicine (R0)